- Home
- RSG vs ALNY Comparison
RSG vs ALNY Comparison
Compare RSG & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSG
- ALNY
- Stock Information
- Founded
- RSG 1996
- ALNY 2002
- Country
- RSG United States
- ALNY United States
- Employees
- RSG N/A
- ALNY N/A
- Industry
- RSG Environmental Services
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- RSG Utilities
- ALNY Health Care
- Exchange
- RSG Nasdaq
- ALNY Nasdaq
- Market Cap
- RSG 73.0B
- ALNY 59.6B
- IPO Year
- RSG 1998
- ALNY 2004
- Fundamental
- Price
- RSG $222.36
- ALNY $458.59
- Analyst Decision
- RSG Buy
- ALNY Strong Buy
- Analyst Count
- RSG 22
- ALNY 29
- Target Price
- RSG $257.52
- ALNY $448.97
- AVG Volume (30 Days)
- RSG 1.2M
- ALNY 1.0M
- Earning Date
- RSG 10-30-2025
- ALNY 10-30-2025
- Dividend Yield
- RSG 1.12%
- ALNY N/A
- EPS Growth
- RSG 13.24
- ALNY N/A
- EPS
- RSG 6.76
- ALNY N/A
- Revenue
- RSG $16,366,000,000.00
- ALNY $2,461,963,000.00
- Revenue This Year
- RSG $5.28
- ALNY $59.55
- Revenue Next Year
- RSG $5.43
- ALNY $40.90
- P/E Ratio
- RSG $32.91
- ALNY N/A
- Revenue Growth
- RSG 5.13
- ALNY 5.01
- 52 Week Low
- RSG $197.61
- ALNY $205.87
- 52 Week High
- RSG $258.75
- ALNY $484.21
- Technical
- Relative Strength Index (RSI)
- RSG 35.09
- ALNY 58.80
- Support Level
- RSG $221.56
- ALNY $446.18
- Resistance Level
- RSG $231.65
- ALNY $465.01
- Average True Range (ATR)
- RSG 2.73
- ALNY 11.41
- MACD
- RSG -0.26
- ALNY -2.05
- Stochastic Oscillator
- RSG 11.12
- ALNY 65.04
About RSG Republic Services Inc.
Republic Services is the second-largest integrated provider of traditional solid waste services in the United States, operating roughly 208 active landfills and 248 transfer stations. The company serves residential, commercial, and industrial end markets. It also runs sizable recycling and hazardous waste collection and disposal operations in North America.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.